The Cancer Research Consortium of West Michigan (CRCWM) is an NCI Community Oncology Research Program (NCORP) comprised of nine major health systems, a renowned basic science institute, and a medical school. CRCWM covers the west half of Michigan and cares for almost 14,000 newly diagnosed cancer patients and their families per year. Formed from two experienced Community Clinical Oncology Programs (CCOPs) in 2014, CRCWM has a 40+ year history of bringing clinical trials to the community and is a major accruer to NCI studies. With over 100 oncology physician investigators and a well-established administrative staff, CRCWM has the ability to enroll patients with cancer diagnoses across the continuum and to address NCI goals of expanding participation of racial/ethnic minorities and underserved in clinical trials. This application reiterates our commitment to high-quality research and ongoing alignment with NCI initiatives. We are well-positioned to achieve our specific aims for the next NCORP grant cycle which are: 1. To maximize accrual of patients to cancer clinical trials sponsored by the National Cancer Institute including priority studies for cancer control/prevention, molecular/precision medicine, and imaging. 2. To be strong contributors to Cancer Care Delivery Research (CCDR). 3. To maximize the sharing of NCI scientific findings into clinical care through education and engagement of clinical partners and health systems. 4. To address health care disparities experienced by underserved (e.g., rural, adolescent/young adult, elderly, minority and underinsured) populations within our communities. 5. To optimize our contribution to the national scientific research agenda by expanding our leadership and committee participation in the National Clinical Trials Network (NCTN)/NCORP research bases and the mentoring of young investigators.
The Cancer Research Consortium of West Michigan (CRCWM) has over 40 years of community-based clinical trial experience and remains dedicated to assuring that every person in West Michigan, regardless of socioeconomic status, race, or geography, has the opportunity to participate in NCTN/NCORP clinical trials for cancer prevention/control, cancer care delivery, and treatment. These trials are the practice-changing research that improve cancer survival, decrease toxicity, and offer better ways to deliver care with decreased costs. Our partnerships with regional health systems allow us to offer over 130 open and accruing cancer research studies, maintain follow-up for 175 additional trials, offer education to targeted populations, and contribute to the knowledge base surrounding the needs of diverse and underserved populations such as children, adolescents and young adults, racial and ethnic minorities, and rural residents.
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|
|Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18|
Showing the most recent 10 out of 13 publications